Fischer Medical Ventures Shares Close Up as Subsidiary Gains Full License to Indonesia's End-TB X-ray Tender

Visakhapatnam, October 16, 2025 – Fischer Medical Ventures Ltd (BSE: 524743; NSE: FISCHER) shares rose more than 2% on Thursday after the news that its fully-owned subsidiary, FMV Global Innovation PTE Ltd, has won full license of Indonesia’s End-TB Handheld X-ray Tender. This achievement reinforces the company’s global reach in diagnostic imaging and public health work.

Stock Market Performance

As of 3:30 PM IST on October 16, the stock closed at ₹95.10, up ₹1.55 or 1.66% for the day. It opened at ₹94.26, touched a high of ₹97.17, and a low of ₹93.21 during the session. The company’s market capitalization stands at ₹6,240 crore with a P/E ratio of 3,216.10. The stock’s 52-week range spans a high of ₹124.70 and a low of ₹77.01.

Licensing Milestone Strengthens Global TB Eradication Mission

FMV Global Innovation is now one of the three fully licensed players in Indonesia’s national tuberculosis (TB) eradication program. Through the acquisition of all three licenses, the subsidiary can now compete in the Indonesian government’s high-impact End-TB Handheld X-ray Tender. The program is key to Indonesia’s vision to end TB by 2030.

With regulatory approval in hand, FMV Global Innovation will play a role in early detection through the use of AI-driven diagnostics, pilot screening initiatives, and high-end molecular testing kits. The programs are designed to enhance TB screening availability in underserved areas throughout Indonesia.

Background: Indonesia’s National Health Drive

Indonesia’s Presidential Regulation No. 67/2021 places TB elimination as a top national health priority. The portable X-ray tender is an integral part of this initiative, enhancing early screening and mobile health accessibility. FMV Global Innovation’s success came after an 11-month licensing experience, facilitated through partnerships with Indian technology suppliers and local partner PT Pariko Medical Ventures to facilitate seamless integration into operations.

Key Milestones

• Licensing Duration: 11 months
• Local Partner: PT Pariko Medical Ventures
• Regulatory Framework: Presidential Regulation No. 67/2021
• TB Elimination Target: 2030

NSE and BSE-listed Fischer Medical Ventures Ltd is a medical equipment and supplies company. The firm’s market capitalization stands at ₹6,213 crore, with shares closing 2.42% higher at ₹95.81 on October 16, 2025, against the previous close of ₹93.55. Fischer continues to pursue the development of affordable, AI-powered healthcare technology for emerging markets, reasserting its global public health and technology innovation commitment.

REF: https://nsearchives.nseindia.com/corporate/FISCHER_16102025130156_PressreleasewithCL.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations